GURU.Markets stock price, segment price, and overall market index valuation
The company's share price VBI Vaccines Inc.
VBI Vaccines is a biotech company developing vaccines. Its stock price reflects both revenue from its already-approved hepatitis B vaccine and the hopes for success of its oncology developments.
Share prices of companies in the market segment - Pharma virus
VBI Vaccines is a biopharmaceutical company developing prophylactic and therapeutic vaccines for the treatment of infectious diseases and cancer. We have classified it in the Pharma: Viruses category. The chart below shows how investors value companies working in the field of vaccinology.
Broad Market Index - GURU.Markets
VBI Vaccines is a biotech company developing vaccines against infectious diseases and cancer. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how VBI shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
VBIV - Daily change in the company's share price VBI Vaccines Inc.
For VBI Vaccines Inc., a biopharmaceutical company, daily volatility reflects sensitivity to its vaccine sales and clinical trial data. This metric is an important element of analysis in this area.
Daily change in the price of a set of shares in a market segment - Pharma virus
VBI Vaccines is a biopharmaceutical company developing vaccines for the prevention and treatment of infectious diseases and cancer. The vaccine sector is highly volatile and driven by news of clinical trials. The chart below reflects average fluctuations in this industry, providing context for evaluating VBIV stock.
Daily change in the price of a broad market stock, index - GURU.Markets
VBI Vaccines is a biotech company developing vaccines against infectious diseases and cancer. Its shares are extremely sensitive to news about clinical trials and pandemics. This event-driven volatility is a clear example of how biotech influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization VBI Vaccines Inc.
VBI Vaccines Inc.'s year-over-year performance tells the story of its performance in the vaccine market. Its 12-month market cap reflects both sales of its hepatitis B vaccine and, more importantly, progress in developing its immunotherapy vaccine for glioblastoma, its main bet for the future.
Annual dynamics of market capitalization of the market segment - Pharma virus
VBI Vaccines is a commercial-stage biopharmaceutical company producing vaccines. Its success depends on the commercialization of its approved hepatitis B vaccine and the results of its R&D. The chart shows how its niche strategy and the competitive environment in the vaccine market influence its performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
VBI Vaccines, a biotech company with an approved product, demonstrates the progression from development to sales. Its performance, compared to the market, reflects investor assessments of both current vaccine revenue and the potential of the remaining drugs in development.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization VBI Vaccines Inc.
VBI Vaccines is a commercial biopharmaceutical company. Its monthly performance reflects both sales of its hepatitis B vaccine and progress in its vaccine development programs, including for COVID-19.
Monthly dynamics of market capitalization of the market segment - Pharma virus
VBI Vaccines is a biotechnology company developing vaccines for the prevention and treatment of infectious diseases and cancer. Its commercial product is a hepatitis B vaccine. The graph below shows the dynamics of the biotech sector, where the development of effective vaccines is a key focus.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
VBI Vaccines is a biotech company developing vaccines. Its shares are driven by news of clinical trials, regulatory approvals, and the commercial success of its vaccines. The company's performance is not tied to overall market trends, but is driven by developments in the medical world.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization VBI Vaccines Inc.
VBI Vaccines, a biotech company developing vaccines, exhibits high volatility. Weekly stock performance depends on news about clinical trials, regulatory decisions, and the commercial success of its products, reflecting the risks and potential in the fight against infectious diseases.
Weekly dynamics of market capitalization of the market segment - Pharma virus
VBI Vaccines shares, like the entire vaccine sector, are moving on a backdrop of news about disease outbreaks and regulatory decisions. Investor sentiment toward the entire industry is creating high volatility. The chart will show how the company stacks up against this backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
VBI Vaccines is a clinical-stage biotech company. Its shares exist in a world of their own, where vaccine trial data is king. The chart clearly demonstrates that VBIV's performance is largely uncorrelated with the market, moving on its own unique news.
Market capitalization of the company, segment and market as a whole
VBIV - Market capitalization of the company VBI Vaccines Inc.
The VBI Vaccines chart is a financial map of the fight against viral diseases. This company's market capitalization reflects not only sales of its hepatitis B vaccine but also hopes for its platform for developing new vaccines, including against cytomegalovirus. Its dynamics are a barometer of its commercial success and progress in clinical development.
VBIV - Share of the company's market capitalization VBI Vaccines Inc. within the market segment - Pharma virus
VBI Vaccines is a biotech company focused on solving complex problems in vaccinology. Its market capitalization reflects the market's confidence in its scientific platform. Its dynamics indicate how close its developments are to becoming commercially successful.
Market capitalization of the market segment - Pharma virus
VBI Vaccines develops next-generation vaccines against infectious diseases and cancer. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect both the enormous hopes for breakthroughs in immunology and the high risks associated with vaccine development.
Market capitalization of all companies included in a broad market index - GURU.Markets
VBI Vaccines is a biotech company developing next-generation vaccines. Its market capitalization chart tells the story of the fight against infectious diseases and cancer. Its volatile price compared to the market reflects the hopes and risks associated with the lengthy clinical trials process.
Book value capitalization of the company, segment and market as a whole
VBIV - Book value capitalization of the company VBI Vaccines Inc.
For VBI Vaccines, book value is its capital and production capacity. The chart below shows the financial and material resources for vaccine development and commercialization. Its dynamics reflect R&D expenditures and investments in establishing its own production facilities.
VBIV - Share of the company's book capitalization VBI Vaccines Inc. within the market segment - Pharma virus
VBI Vaccines is a biotech company developing vaccines. Its in-house manufacturing capabilities are a key advantage. The asset share chart shows how its physical infrastructure, including a modern manufacturing facility, enables it to oversee the production of innovative vaccines.
Market segment balance sheet capitalization - Pharma virus
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, VBI Vaccines, which develops vaccines, appears "light" at the R&D stage. However, unlike pills, vaccine production requires the construction of complex and capital-intensive bioreactor plants, which presents a future challenge for the company.
Book value of all companies included in the broad market index - GURU.Markets
VBI Vaccines develops vaccines against infectious diseases and cancer. The company's assets are not giant factories, but rather a scientific platform (virus-like particles) and clinical trial data. The company's balance sheet is the value of the "immune shield" they create to protect people from real biological threats.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - VBI Vaccines Inc.
VBI Vaccines' balance sheet is its cash and scientific platform. Its market capitalization is a bet on the commercial success of its hepatitis B vaccine and other developments. The MvsBCap_Co chart shows how much the "hope" of defeating viruses is worth compared to the company's actual assets.
Market to book capitalization ratio in a market segment - Pharma virus
VBI Vaccines is a biopharmaceutical company developing vaccines, including those for hepatitis B. The chart shows how the market values its commercial product and the scientific platform for creating new vaccines. The valuation is heavily dependent on sales data and clinical trial results.
Market to book capitalization ratio for the market as a whole
VBI Vaccines is a biopharmaceutical company developing vaccines. Its market valuation depends almost entirely on the success of clinical trials and investor confidence in future drugs. The chart shows a typical biotech gap: a modest book value and a market capitalization based solely on breakthrough expectations.
Debts of the company, segment and market as a whole
VBIV - Company debts VBI Vaccines Inc.
For VBI Vaccines, a biopharmaceutical company, debt is a key resource for bringing vaccines to market. This chart shows how the company raises capital to conduct late-stage clinical trials and commercialize its products, such as the hepatitis B vaccine. Debt is the bridge between development and saving lives.
Market segment debts - Pharma virus
VBI Vaccines is a biotechnology company developing vaccines for the prevention and treatment of infectious diseases and cancer. Vaccine development is a long, expensive, and risky process. This chart shows how the company funds its research programs and manufacturing processes at the clinical and early commercial stages.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio VBI Vaccines Inc.
VBI Vaccines is a biotech company developing vaccines. This process requires lengthy and expensive clinical trials. This chart shows how reliant the company is on external capital to fund its research. It reflects the high financial risk inherent in vaccine development, where success is never guaranteed.
Market segment debt to market segment book capitalization - Pharma virus
VBI Vaccines is a biopharmaceutical company developing vaccines against infectious diseases and cancer. Vaccine development and clinical trials are lengthy and capital-intensive processes. The chart shows how the company's debt load for R&D funding compares to the market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
VBI Vaccines (VBIV) is a biopharmaceutical company developing vaccines against infectious diseases and in immuno-oncology. During the research and development phase, these companies rely on equity capital. This chart shows the overall market leverage, clearly illustrating why the biotech financing model is radically different from that of mature industries.
P/E of the company, segment and market as a whole
P/E - VBI Vaccines Inc.
This metric for VBI Vaccines, a biopharmaceutical company, shows the valuation of its vaccine platform. P/E is likely absent. The company's value depends on the success of its commercial hepatitis B vaccine and progress in developing therapeutic vaccines, such as those for cancer. The chart's dynamics reflect confidence in its scientific developments.
P/E of the market segment - Pharma virus
This chart shows the average P/E ratio for biotech companies. For VBI Vaccines, with its hepatitis B vaccine, this is an important benchmark. Comparing its P/E to the industry average helps understand how investors view its commercial success and the potential of its research platform compared to other vaccine companies.
P/E of the market as a whole
VBI Vaccines develops vaccines for the prevention and treatment of infectious diseases and cancer. The company uses its innovative platform to create more effective vaccines. This chart shows sentiment in the biotech sector. It helps understand whether the market believes in the technological advantage of VBI's platform and how news about clinical trials impacts its valuation compared to overall trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company VBI Vaccines Inc.
VBI Vaccines is a biopharmaceutical company developing vaccines for the prevention and treatment of infectious diseases and cancer. This chart reflects analyst expectations regarding the commercial launch of its hepatitis B vaccine and the success of clinical trials of other candidates. It serves as a barometer of confidence in future revenue from its pipeline.
%20P%2FE%20VBI%20Vaccines%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-VBI-Vaccines-Inc.&v=1772695771038 "Chart of the company's future (projected) P/E VBI Vaccines Inc.")
Future (projected) P/E of the market segment - Pharma virus
VBI Vaccines Inc. develops vaccines for the prevention and treatment of infectious diseases and cancer. This chart shows average expectations for the biotech sector. VBIV's position may indicate the level of investor confidence in its scientific platform, particularly its hepatitis B vaccine and other developments in clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772695771106 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
VBI Vaccines develops vaccines, including against hepatitis B. The company's success depends on clinical trial results and regulatory approvals, not economic cycles. However, overall investor sentiment, as reflected in this chart, influences the availability of capital to fund research and development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772695771149 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit VBI Vaccines Inc.
VBI Vaccines Inc. is a biotechnology company developing vaccines for the prevention and treatment of infectious diseases and cancer. This chart shows the long journey from the laboratory to the market. Periods of loss reflect clinical trial costs, while potential profit growth will be driven by the approval and commercial success of its vaccines, such as the hepatitis B vaccine.
Profit of companies in the market segment - Pharma virus
VBI Vaccines Inc. develops vaccines for the prevention and treatment of infectious diseases and cancer. Profitability in the antiviral drug sector, as this chart shows, can be explosive if a product is successful and approved. For VBIV, as for other biotechs, this is a high-stakes game, where years of research can pay off handsomely with a single breakthrough.
Overall market profit
VBI Vaccines is a biopharmaceutical company whose success is determined by science and healthcare needs, not economics. The development of vaccines for hepatitis B or COVID-19 is not dependent on the phase of the cycle shown by this chart. However, the overall market situation influences investor sentiment and the company's ability to raise capital to fund its research and development.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company VBI Vaccines Inc.
VBI Vaccines develops vaccines for infectious diseases and immuno-oncology. This chart shows analysts' forecasts for future profits, which are contingent on the success of clinical trials and regulatory approvals. This represents the company's financial expectations that its scientific developments will translate into commercially successful vaccines.
%20profit%20of%20the%20company%20VBI%20Vaccines%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-VBI-Vaccines-Inc.&v=1772695771217 "Graph of future (projected) profit of the company VBI Vaccines Inc.")
Future (predicted) profit of companies in the market segment - Pharma virus
VBI Vaccines develops vaccines for the prevention and treatment of infectious diseases and cancer, including a hepatitis B vaccine. The company's success depends on regulatory approval and clinical implementation. This chart shows the profitability forecast for the vaccine sector, reflecting expectations for government procurement and demand for new immunotherapeutics.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772695771225 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
VBI Vaccines is a biopharmaceutical company developing vaccines. Its success depends on clinical trial results and regulatory approval, not economic cycles. However, the overall earnings outlook is important for assessing investor sentiment. During downturns, raising the capital needed for expensive research becomes more challenging.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772695771237 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - VBI Vaccines Inc.
VBI Vaccines is a biopharmaceutical company with an approved hepatitis B vaccine and promising developments in oncology. This chart shows how the market values its current revenue while also factoring in the enormous potential of its scientific platform, which could set new standards in the prevention and treatment of serious diseases.
P/S market segment - Pharma virus
VBI Vaccines develops vaccines for the prevention and treatment of infectious diseases and cancer, including a hepatitis B vaccine. The chart shows the average revenue estimate for the biotech industry. It allows one to assess whether investor expectations for its scientific platform and the commercial potential of its vaccines are higher or lower than the sector average.
P/S of the market as a whole
VBI Vaccines is a biopharmaceutical company developing vaccines for the prevention and treatment of infectious diseases and cancer. Its future depends on the success of clinical trials and the commercialization of its products. The chart helps understand the market's expectations for future revenues factored into the company's current valuation, compared to the average for mature businesses.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company VBI Vaccines Inc.
VBI Vaccines is a biopharmaceutical company developing vaccines, including for hepatitis B. The chart shows how the market values its scientific potential. The company's value is determined by the projected future revenue from its vaccines if they are approved and successfully commercialized, which is a bet on a scientific breakthrough.
%20P%2FS%20VBI%20Vaccines%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-VBI-Vaccines-Inc.&v=1772695771294 "The graph of the company's future (projected) P/S VBI Vaccines Inc.")
Future (projected) P/S of the market segment - Pharma virus
VBI Vaccines develops vaccines for the prevention and treatment of infectious diseases and cancer using its innovative platform. This figure shows the average future revenue estimates for pharmaceutical companies in its profile. This helps assess how highly investors value VBI's technology and the commercial potential of its vaccine candidates compared to competitors.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772695771312 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
VBI Vaccines Inc. is a biopharmaceutical company developing vaccines. Its future depends on the success of clinical trials and regulatory approval. This indicator of overall revenue expectations is of little significance for the company. Investors in VBIV focus not on macroeconomics but on the scientific data on its hepatitis B vaccines and other developments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772695771339 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales VBI Vaccines Inc.
VBI Vaccines is a biopharmaceutical company developing vaccines. Its revenue, shown in this chart, may consist of sales of approved products, such as the hepatitis B vaccine, as well as payments from co-development partners. Sales growth reflects successful commercialization and research progress.
Sales of companies in the market segment - Pharma virus
VBI Vaccines Inc. is a biopharmaceutical company developing vaccines for the prevention and treatment of infectious diseases and cancer. The company uses innovative technologies to create more effective immune responses. This chart shows the total revenue for the sector, reflecting the level of investment and commercial progress in the development of new vaccines.
Overall market sales
VBI Vaccines is a biopharmaceutical company developing vaccines to prevent infectious diseases. Its success depends on regulatory approval and government vaccination programs. The overall economic situation, shown in this chart, influences healthcare system budgets and their willingness to purchase new vaccines.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company VBI Vaccines Inc.
VBI Vaccines develops vaccines for the prevention and treatment of infectious diseases and cancer. Its revenue depends on the commercial success of its currently approved hepatitis B vaccine and the progress of other candidates in clinical trials. This chart reflects the company's sales forecasts and research expectations.
%20sales%20of%20the%20company%20VBI%20Vaccines%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-VBI-Vaccines-Inc.&v=1772695771445 "Schedule of future (projected) sales of the company VBI Vaccines Inc.")
Future (projected) sales of companies in the market segment - Pharma virus
VBI Vaccines develops next-generation vaccines for the prevention and treatment of infectious diseases and cancer, including a hepatitis B vaccine. This chart shows the outlook for the entire virus-focused pharmaceutical sector. The company's success depends on regulatory approval and the commercialization of its innovative vaccine platforms.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772695771464 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
VBI Vaccines develops vaccines for the prevention and treatment of infectious diseases and cancer. The company's success depends on research results and government contracts for vaccination programs. The overall economic situation, reflected in this chart, affects healthcare system budgets and their ability to finance the procurement of new, more effective vaccines in the future.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772695771529 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality VBI Vaccines Inc.
VBI Vaccines is a biopharmaceutical company developing vaccines, including for hepatitis B. Its financial performance reflects its journey from research to commercialization. This chart shows the balance between high R&D costs and potential future profitability if its vaccines are successful and widely adopted.
Market segment marginality - Pharma virus
VBI Vaccines is a biopharmaceutical company developing vaccines for the prevention and treatment of infectious diseases and cancer. This chart shows the average revenue in the pharmaceutical industry. The company's success and its ability to exceed this figure depend on the approval and commercial launch of its vaccines, particularly for hepatitis B, in a competitive global market.
Market marginality as a whole
VBI Vaccines Inc. is a biopharmaceutical company developing vaccines for the prevention and treatment of infectious diseases and cancer. Its financial performance is driven by clinical trial costs and the potential of its scientific platform. This total return chart contrasts starkly with the risky and lengthy journey of vaccine development and the stable profitability of established companies.
Employees in the company, segment and market as a whole
Number of employees in the company VBI Vaccines Inc.
VBI Vaccines is a biotechnology company developing innovative vaccines for the prevention and treatment of infectious diseases and cancer. This chart shows the size of its research team. For a company at this stage, the size of its research team reflects its investment in research and development to advance vaccine candidates through clinical trials.
Share of the company's employees VBI Vaccines Inc. within the market segment - Pharma virus
VBI Vaccines is a biotechnology company developing a new generation of vaccines, including those against hepatitis B and COVID-19. Vaccine development is a complex scientific process. This chart shows the proportion of highly qualified virologists and immunologists VBI attracts. It reflects its scientific focus and the concentration of talent working on the front lines of infection control.
Number of employees in the market segment - Pharma virus
VBI Vaccines Inc. is a biopharmaceutical company developing prophylactic and therapeutic vaccines. The dynamics of its scientific and clinical team size, as shown in the graph, are closely linked to the stages of vaccine development. Hiring often accelerates as vaccine candidates enter late-stage clinical trials or are preparing for manufacturing.
Number of employees in the market as a whole
VBI Vaccines is at the forefront of the fight against infectious diseases, developing innovative vaccines. This chart shows how the biotech company is preparing for breakthroughs. Staff growth, particularly in clinical research and manufacturing, is a key signal of progress in development and the approach to vaccine commercialization.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company VBI Vaccines Inc. (VBIV)
VBI Vaccines is a biotech company developing vaccines. Like most scientific startups, its market capitalization is based not on current sales, but on the potential of its scientific platforms and patents. This chart shows how highly the market values the intellectual capital generated by a small but highly skilled team of virologists and researchers.
%20of%20the%20company%20VBI%20Vaccines%20Inc.%20(VBIV)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-VBI-Vaccines-Inc.-VBIV&v=1772695771915 "Chart of market capitalization per employee (in thousands of dollars) of the company VBI Vaccines Inc. (VBIV)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
VBI Vaccines is a biopharmaceutical company developing next-generation vaccines, including for hepatitis B. Its value lies in its scientific platform and clinical data, not in its large staff. This chart illustrates how investors evaluate the potential of its technologies per research team member.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772695772027 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
VBI Vaccines is a biopharmaceutical company developing vaccines for the prevention and treatment of infectious diseases and cancer. The chart shows the market valuation of the R&D platform. The high market capitalization per employee reflects the potential value of their vaccine technologies, which have the potential to prevent diseases on a global scale.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772695772046 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company VBI Vaccines Inc. (VBIV)
VBI Vaccines is a biotech company developing vaccines (for example, for hepatitis B and COVID-19). The company has an approved product. This chart shows how successfully the company is commercializing its R&D. Revenue per employee (scientist, marketer) is an indicator of the market success of their vaccines.
%20Chart%20VBI%20Vaccines%20Inc.%20(VBIV)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-VBI-Vaccines-Inc.-VBIV&v=1772695772127 "Company Profit Per Employee (in thousands of dollars) Chart VBI Vaccines Inc. (VBIV)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
VBI Vaccines is a biotech company developing vaccines, including a preventative hepatitis B vaccine and therapeutic cancer vaccines. This chart shows how effectively the company commercializes its approved products and invests in R&D. It serves as a benchmark for assessing how successful VBI is in the highly competitive vaccine race compared to the pharma giants.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772695772233 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
VBI Vaccines is a biopharmaceutical company with an approved hepatitis B vaccine (PreHevbrio) and an R&D platform for developing other vaccines. This chart shows how effectively the company utilizes its staff to commercialize its new product while continuing to invest in research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772695772280 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee VBI Vaccines Inc. (VBIV)
VBI Vaccines Inc. develops vaccines to combat infectious diseases. For a biotech company, this chart reflects progress in commercialization. Increases in revenue per employee may be due to sales of the approved vaccine or payments from partners for joint development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-VBI-Vaccines-Inc.-VBIV&v=1772695772299 "Sales chart per company employee VBI Vaccines Inc. (VBIV)")
Sales per employee in the market segment - Pharma virus
VBI Vaccines (VBIV) is a biotech company with both an approved hepatitis B vaccine (PreHevbrio) and R&D programs. This graph shows their early commercial phase. Revenue per employee will depend on how successfully their sales team can capture market share from competitors like GSK. While sales are low, productivity will be low.
Sales per employee for the market as a whole
VBI Vaccines is a biotech company focused on vaccines, including their approved hepatitis B drug. This graph shows the transition from R&D to commercialization. It measures how effectively their commercial team (sales and marketing) grows revenue by leveraging the intellectual property created by their R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company VBI Vaccines Inc. (VBIV)
VBI Vaccines (VBIV) is a biotech company specializing in vaccines. Their breakthrough is the hepatitis B vaccine (PreHevbrio), which targets segments where older vaccines are ineffective. This chart highlights bearish bets. Are the bears doubting the commercial success of their vaccine or whether the company has the resources to market and develop it?
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-VBI-Vaccines-Inc.-VBIV&v=1772695772381 "Short Shares Chart for the Company VBI Vaccines Inc. (VBIV)")
Shares shorted by market segment - Pharma virus
VBI Vaccines is a biotech company developing vaccines, including those against hepatitis B and coronaviruses. Vaccine development is a high-risk, high-reward field. This chart shows the overall bearish sentiment across the vaccine sector. If it's rising, it means investors are generally skeptical of the sector, possibly due to research setbacks or market saturation.
Shares shorted by the overall market
VBI Vaccines is a biotech company focused on vaccine development. This chart illustrates the overall market pessimism. When fear prevails, investors are reluctant to finance the "burning" of cash. They sell off shares of pre-profitable companies like VBIV, fearing they won't have enough capital to complete R&D in a market panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator VBI Vaccines Inc. (VBIV)
VBI Vaccines (VBIV) is a biotech company developing vaccines, including the approved PreHevbrio (hepatitis B vaccine) and COVID-19 candidates. This oscillator measures momentum. It shows when the stock is "overheated" (above 70) on trial news or "oversold" (below 30) due to a slow commercial launch.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-VBI-Vaccines-Inc.-VBIV&v=1772695772496 "RSI 14 indicator chart for the company's stock VBI Vaccines Inc. (VBIV)")
RSI 14 Market Segment - Pharma virus
VBI Vaccines is a "biotech" *vaccinator* (Canada/USA). Their "thing" is a *platform* (eVLP) for creating *vaccines* (hepatitis B, COVID) and *immunotherapy* for cancer. The "Pharma virus" (biotech/vaccines) sector thrives on news. RSI_14_Seg shows the "temperature" of *the entire* segment. It helps us understand: is VBIV's growth due to their R&D, or is *the entire* biotech "overheated"?
RSI 14 for the overall market
VBI Vaccines (VBIV) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VBIV (VBI Vaccines Inc.)
VBI Vaccines is a biotech company that has developed vaccines, including PreHevbrio, a hepatitis B vaccine for adults. This chart shows the analysts' average 12-month forecast. It reflects their view on the commercial success of PreHevbrio and the potential of their R&D platform (including a COVID vaccine).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VBIV-VBI-Vaccines-Inc.&v=1772695772645 "A chart showing analyst consensus forecasts for the expected stock price. VBIV (VBI Vaccines Inc.)")
The difference between the consensus estimate and the actual stock price VBIV (VBI Vaccines Inc.)
VBI Vaccines (VBIV) is a biotech company that developed PreHevbrio, a next-generation vaccine for hepatitis B. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in the commercial success of this vaccine and their oncology R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VBIV-VBI-Vaccines-Inc.&v=1772695772661 "A chart showing the difference between the consensus forecast and the actual stock price. VBIV (VBI Vaccines Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
VBI Vaccines (VBIV) is a biotech company that has developed an advanced hepatitis B vaccine, as well as an R&D platform for COVID and cancer vaccines. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe this new vaccine will be commercially successful.
Analysts' consensus forecast for the overall market share price
VBI Vaccines (VBIV) is a virus hunter. This biotech company has already commercialized a breakthrough Hepatitis B vaccine (PreHevbrio) and is developing cancer vaccines. This chart shows the overall risk appetite. It reflects the willingness of investors to invest in biotech companies that have already transitioned from "science" to "sales" but still require capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index VBI Vaccines Inc.
VBI Vaccines is a biotech company developing vaccines, including a hepatitis B vaccine (PreHevbrio), which is already approved in the US and Europe. Their focus is immunology and infectious diseases. This chart is a composite index assessing the commercial launch of their lead vaccine, the potential of other developments (e.g., against COVID), and overall financial strength.
AKIMA Market Segment Index - Pharma virus
VBI Vaccines (VBIV) is a pharmaceutical company specializing in antiviral drugs. They are a biotech company specializing in vaccines. Their key product is PreHevbrio, an advanced hepatitis B vaccine. This chart compares their composite index to the vaccine sector average.
The AKIM Index for the overall market
VBI Vaccines is a biopharmaceutical company that developed a hepatitis B vaccine (PreHevbrio). It went through bankruptcy/restructuring. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this commercially volatile company stacks up against overall trends.
